Drug class

Antineoplastic Monoclonal Antibodies

Antineoplastic monoclonal antibodies are a major class of targeted biologic therapeutics designed to bind specific antigens expressed on malignant cells or within the tumor microenvironment. Read more about Antineoplastic Monoclonal Antibodies

29 drugs in this class 21 manufacturers

Advertisement

Drugs in Antineoplastic Monoclonal Antibodies

Showing 1–9 of 29 drugs

KESIMPTA PEN (ofatumumab)

ANTINEOPLASTIC MONOCLONAL ANTIBODIES · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
Novartis Pharmaceuticals

RITUXAN (rituximab)

ANTINEOPLASTIC MONOCLONAL ANTIBODIES · RELAPSE OR REFRACTORY NON-HODGKIN'S LYMPHOMA ·+10
GENENTECH

ARZERRA (ofatumumab)

ANTINEOPLASTIC MONOCLONAL ANTIBODIES · CHRONIC LYMPHOCYTIC LEUKEMIA ·+2
Novartis Pharmaceuticals
Filter & compare in the drug finder → Opens the drug finder with Antineoplastic Monoclonal Antibodies preselected. Add indication or manufacturer filters there.

About Antineoplastic Monoclonal Antibodies.

Antineoplastic monoclonal antibodies are a major class of targeted biologic therapeutics designed to bind specific antigens expressed on malignant cells or within the tumor microenvironment.

By recognizing defined molecular targets, these agents exert anti-tumor activity through multiple mechanisms, including blocking oncogenic signaling pathways, promoting immune-mediated cytotoxicity, inhibiting tumor angiogenesis, or selectively delivering cytotoxic payloads as antibody-drug conjugates.

Clinically, this drug class plays a central role across diverse oncologic diseases, including hematologic malignancies such as leukemias, lymphomas, and multiple myeloma, as well as numerous solid tumors, including breast, colorectal, lung, and melanoma.